Tenofovir alafenamide (TAF)

Published February 2016; Updated October 2017
Susa Coffey, MD
Selected Reference
7. Pozniak A, Arribas JR, Gathe J, et al; GS-US-292-1249 Study Investigators. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, phase 3 study. J Acquir Immune Defic Syndr. 2015 Nov 30. [Epub ahead of print]